Copyright Reports & Markets. All rights reserved.

Global Non-small Cell Lung Cancer Therapeutics Market Research Report 2019

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Non-small Cell Lung Cancer Therapeutics Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Non-small Cell Lung Cancer Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Alimta
    • 1.4.3 Iressa
    • 1.4.4 Avastin
    • 1.4.5 Tarceva
    • 1.4.6 Zykadia
    • 1.4.7 Tagrisso
    • 1.4.8 Xalkori
    • 1.4.9 Cyramza
    • 1.4.10 Opdivo
    • 1.4.11 Alecensa
  • 1.5 Market by Application
    • 1.5.1 Global Non-small Cell Lung Cancer Therapeutics Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Non-small Cell Lung Cancer Therapeutics Market Perspective (2015-2026)
  • 2.2 Global Non-small Cell Lung Cancer Therapeutics Growth Trends by Regions
    • 2.2.1 Non-small Cell Lung Cancer Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Non-small Cell Lung Cancer Therapeutics Historic Market Share by Regions (2015-2020)
    • 2.2.3 Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Non-small Cell Lung Cancer Therapeutics Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Non-small Cell Lung Cancer Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Market Size
    • 3.1.1 Global Top Non-small Cell Lung Cancer Therapeutics Players by Revenue (2015-2020)
    • 3.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Non-small Cell Lung Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio
    • 3.2.1 Global Non-small Cell Lung Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Non-small Cell Lung Cancer Therapeutics Revenue in 2019
  • 3.3 Non-small Cell Lung Cancer Therapeutics Key Players Head office and Area Served
  • 3.4 Key Players Non-small Cell Lung Cancer Therapeutics Product Solution and Service
  • 3.5 Date of Enter into Non-small Cell Lung Cancer Therapeutics Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Non-small Cell Lung Cancer Therapeutics Historic Market Size by Type (2015-2020)
  • 4.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)
  • 5.2 Global Non-small Cell Lung Cancer Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 6.2 Non-small Cell Lung Cancer Therapeutics Key Players in North America (2019-2020)
  • 6.3 North America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 6.4 North America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 7.2 Non-small Cell Lung Cancer Therapeutics Key Players in Europe (2019-2020)
  • 7.3 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 7.4 Europe Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

8 China

  • 8.1 China Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 8.2 Non-small Cell Lung Cancer Therapeutics Key Players in China (2019-2020)
  • 8.3 China Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 8.4 China Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 9.2 Non-small Cell Lung Cancer Therapeutics Key Players in Japan (2019-2020)
  • 9.3 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 9.4 Japan Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 10.2 Non-small Cell Lung Cancer Therapeutics Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

11 India

  • 11.1 India Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 11.2 Non-small Cell Lung Cancer Therapeutics Key Players in India (2019-2020)
  • 11.3 India Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 11.4 India Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size (2015-2020)
  • 12.2 Non-small Cell Lung Cancer Therapeutics Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Type (2015-2020)
  • 12.4 Central & South America Non-small Cell Lung Cancer Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 GlaxoSmithKline
    • 13.1.1 GlaxoSmithKline Company Details
    • 13.1.2 GlaxoSmithKline Business Overview
    • 13.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.1.4 GlaxoSmithKline Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020))
    • 13.1.5 GlaxoSmithKline Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview
    • 13.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.2.4 Novartis Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 AstraZeneca
    • 13.3.1 AstraZeneca Company Details
    • 13.3.2 AstraZeneca Business Overview
    • 13.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.3.4 AstraZeneca Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.3.5 AstraZeneca Recent Development
  • 13.4 Roche
    • 13.4.1 Roche Company Details
    • 13.4.2 Roche Business Overview
    • 13.4.3 Roche Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.4.4 Roche Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.4.5 Roche Recent Development
  • 13.5 Bristol-Myers Squibb
    • 13.5.1 Bristol-Myers Squibb Company Details
    • 13.5.2 Bristol-Myers Squibb Business Overview
    • 13.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.5.4 Bristol-Myers Squibb Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.5.5 Bristol-Myers Squibb Recent Development
  • 13.6 Pfizer
    • 13.6.1 Pfizer Company Details
    • 13.6.2 Pfizer Business Overview
    • 13.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.6.4 Pfizer Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.6.5 Pfizer Recent Development
  • 13.7 Eli Lilly
    • 13.7.1 Eli Lilly Company Details
    • 13.7.2 Eli Lilly Business Overview
    • 13.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.7.4 Eli Lilly Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.7.5 Eli Lilly Recent Development
  • 13.8 Sanofi
    • 13.8.1 Sanofi Company Details
    • 13.8.2 Sanofi Business Overview
    • 13.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Introduction
    • 13.8.4 Sanofi Revenue in Non-small Cell Lung Cancer Therapeutics Business (2015-2020)
    • 13.8.5 Sanofi Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Non-small Cell Lung Cancer Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non-small Cell Lung Cancer Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    GlaxoSmithKline
    Novartis
    AstraZeneca
    Roche
    Bristol-Myers Squibb
    Pfizer
    Eli Lilly
    Sanofi

    Market segment by Type, the product can be split into
    Alimta
    Iressa
    Avastin
    Tarceva
    Zykadia
    Tagrisso
    Xalkori
    Cyramza
    Opdivo
    Alecensa
    Market segment by Application, split into
    Hospital
    Clinic

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now